DE60204951D1 - Ccr5 antagonisten verwendbar für die behandlung von aids - Google Patents

Ccr5 antagonisten verwendbar für die behandlung von aids

Info

Publication number
DE60204951D1
DE60204951D1 DE60204951T DE60204951T DE60204951D1 DE 60204951 D1 DE60204951 D1 DE 60204951D1 DE 60204951 T DE60204951 T DE 60204951T DE 60204951 T DE60204951 T DE 60204951T DE 60204951 D1 DE60204951 D1 DE 60204951D1
Authority
DE
Germany
Prior art keywords
aids
treatment
ccr5 antagonists
antagonists use
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60204951T
Other languages
English (en)
Other versions
DE60204951T2 (de
Inventor
W Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60204951D1 publication Critical patent/DE60204951D1/de
Application granted granted Critical
Publication of DE60204951T2 publication Critical patent/DE60204951T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE60204951T 2001-03-29 2002-03-27 Ccr5 antagonisten verwendbar für die behandlung von aids Expired - Lifetime DE60204951T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
US279938P 2001-03-29
PCT/US2002/009491 WO2002079194A1 (en) 2001-03-29 2002-03-27 Ccr5 antagonists useful for treating aids

Publications (2)

Publication Number Publication Date
DE60204951D1 true DE60204951D1 (de) 2005-08-11
DE60204951T2 DE60204951T2 (de) 2006-05-11

Family

ID=23070981

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60204951T Expired - Lifetime DE60204951T2 (de) 2001-03-29 2002-03-27 Ccr5 antagonisten verwendbar für die behandlung von aids
DE60236218T Expired - Lifetime DE60236218D1 (de) 2001-03-29 2002-03-27 CCR5 Antagonisten verwendbar für die Behandlung von Aids

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60236218T Expired - Lifetime DE60236218D1 (de) 2001-03-29 2002-03-27 CCR5 Antagonisten verwendbar für die Behandlung von Aids

Country Status (30)

Country Link
US (5) US6720325B2 (de)
EP (2) EP1373256B1 (de)
JP (2) JP4248251B2 (de)
KR (1) KR100613528B1 (de)
CN (1) CN100519554C (de)
AR (1) AR033452A1 (de)
AT (2) ATE466009T1 (de)
AU (1) AU2002255947B8 (de)
BR (1) BR0208398A (de)
CA (1) CA2442227C (de)
CZ (1) CZ20032636A3 (de)
DE (2) DE60204951T2 (de)
DK (1) DK1373256T3 (de)
ES (2) ES2242856T3 (de)
HK (2) HK1057363A1 (de)
HU (1) HUP0400349A3 (de)
IL (1) IL157551A0 (de)
MX (1) MXPA03008853A (de)
MY (1) MY128609A (de)
NO (1) NO326349B1 (de)
NZ (1) NZ527768A (de)
PE (1) PE20020996A1 (de)
PL (1) PL364560A1 (de)
PT (1) PT1373256E (de)
RU (1) RU2316553C2 (de)
SI (1) SI1373256T1 (de)
SK (1) SK287521B6 (de)
TW (1) TWI237638B (de)
WO (1) WO2002079194A1 (de)
ZA (1) ZA200307474B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157551A0 (en) * 2001-03-29 2004-03-28 Schering Corp Ccr5 antagonists useful for treating aids
EP1604982A1 (de) 2001-07-02 2005-12-14 AstraZeneca AB Zwischenverbindungen für die herstellung von piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US7452992B2 (en) 2002-12-13 2008-11-18 Smithkline Beecham Corporation Heterocyclic compounds as CCR5 antagonists
PE20040769A1 (es) 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
WO2005042517A2 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
EP1725235B1 (de) * 2004-02-05 2009-04-15 Schering Corporation Piperidin-derivate als ccr3-antagonisten
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
KR101235090B1 (ko) 2004-04-13 2013-02-20 인사이트 코포레이션 케모킨 수용체 길항제로서의 피페라지닐피페리딘 유도체
PE20090123A1 (es) 2004-09-13 2009-03-10 Ono Pharmaceutical Co Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
DE602006017507D1 (de) * 2005-01-06 2010-11-25 Schering Corp Synthese von ccr5 rezeptor antagonisten
US7521452B2 (en) 2005-01-06 2009-04-21 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
PE20061012A1 (es) * 2005-02-23 2006-10-03 Schering Corp Derivados piperidinil piperazina como inhibidores de receptores quiomicina
EP1858886A1 (de) * 2005-02-23 2007-11-28 Schering Corporation Als inhibitoren von chemokinrezeptoren geeignete piperidinylpiperidinderivate
MX2008000821A (es) 2005-07-21 2008-03-19 Astrazeneca Ab Nuevos derivados de piperidina.
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU6253996A (en) 1995-06-07 1996-12-30 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein in absorbent article
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (de) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkane als CCR5-Modulatoren
KR100439357B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
RU2299206C9 (ru) * 1999-05-04 2007-11-20 Шеринг Корпорейшн Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5
IL157551A0 (en) * 2001-03-29 2004-03-28 Schering Corp Ccr5 antagonists useful for treating aids

Also Published As

Publication number Publication date
US7008946B2 (en) 2006-03-07
IL157551A0 (en) 2004-03-28
ES2242856T3 (es) 2005-11-16
EP1373256A1 (de) 2004-01-02
US7060701B2 (en) 2006-06-13
CA2442227C (en) 2008-10-28
US20030008877A1 (en) 2003-01-09
EP1591444B1 (de) 2010-04-28
SI1373256T1 (sl) 2005-12-31
US20060063771A1 (en) 2006-03-23
NZ527768A (en) 2005-03-24
JP2004525157A (ja) 2004-08-19
PE20020996A1 (es) 2002-11-01
WO2002079194A1 (en) 2002-10-10
DK1373256T3 (da) 2005-10-10
MXPA03008853A (es) 2003-12-04
PT1373256E (pt) 2005-11-30
ATE466009T1 (de) 2010-05-15
AU2002255947B2 (en) 2005-10-27
TWI237638B (en) 2005-08-11
RU2316553C2 (ru) 2008-02-10
KR100613528B1 (ko) 2006-08-16
US20040157854A1 (en) 2004-08-12
NO20034311D0 (no) 2003-09-26
BR0208398A (pt) 2004-06-15
ES2342942T3 (es) 2010-07-19
KR20030083014A (ko) 2003-10-23
EP1591444A1 (de) 2005-11-02
CN1547580A (zh) 2004-11-17
ATE299139T1 (de) 2005-07-15
JP2008074862A (ja) 2008-04-03
CZ20032636A3 (cs) 2003-12-17
CA2442227A1 (en) 2002-10-10
US6720325B2 (en) 2004-04-13
US20050143390A1 (en) 2005-06-30
CN100519554C (zh) 2009-07-29
US7098213B2 (en) 2006-08-29
MY128609A (en) 2007-02-28
DE60236218D1 (de) 2010-06-10
PL364560A1 (en) 2004-12-13
EP1373256B1 (de) 2005-07-06
NO326349B1 (no) 2008-11-17
SK287521B6 (sk) 2010-12-07
AR033452A1 (es) 2003-12-17
HUP0400349A3 (en) 2010-03-29
HUP0400349A2 (hu) 2004-12-28
US6900211B2 (en) 2005-05-31
JP4248251B2 (ja) 2009-04-02
US20050059666A1 (en) 2005-03-17
HK1083505A1 (en) 2006-07-07
DE60204951T2 (de) 2006-05-11
HK1057363A1 (en) 2004-04-02
ZA200307474B (en) 2004-12-24
NO20034311L (no) 2003-11-26
SK11962003A3 (sk) 2004-03-02
AU2002255947B8 (en) 2005-11-17
RU2003131879A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ATE451921T1 (de) Phenylindole zur behandlung von hiv
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
DE602004008631D1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne
DE60025403D1 (de) Kit zur behandlung von malaria die chloroquin und bulaquin enthält
ATE335500T1 (de) Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition